Current Strategies for the Multidisciplinary Management of Resectable and Locally Advanced Pancreatic Cancer

Authors

  • Roberto Lázaro Blanco Sosa Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Universidad Nacional Autónoma de México, Servicio de Cirugía Hepatopancreatobiliar. Ciudad de México, México. https://orcid.org/0000-0001-9475-9517
  • Olivia El Achtar Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Universidad Nacional Autónoma de México, Servicio de Cirugía Hepatopancreatobiliar. Ciudad de México, México. https://orcid.org/0000-0002-2230-836X
  • Milton Manuel Sánchez García Hospital Clínico Quirúrgico "Hermanos Ameijeiras", Universidad de Ciencias Médicas de La Habana, Servicio de Cirugía Hepatopancreatobiliar. La Habana, Cuba. https://orcid.org/0000-0002-7333-9107
  • Carlos David Garcia Martin Hospital Regional de Huehuetenango. Universidad Mariano Gálvez de Guatemala, Servicio de Cirugía General. Huehuetenango, Guatemala. https://orcid.org/0009-0002-3273-4247

Keywords:

Neoplasias pancreáticas, comunicación interdisciplinaria, cambio de tratamiento.

Abstract

Introduction: Pancreatic cancer is one of the most lethal malignancies of the digestive tract, with a low five-year survival rate. Its clinical and biological complexity requires a comprehensive therapeutic approach. In resectable and locally advanced stages, only multidisciplinary management can improve clinical outcomes.
Objective: To critically review and update current strategies for the multidisciplinary management of pancreatic cancer in resectable and locally advanced stages.
Methods: A systematic review of the scientific literature was conducted in PubMed, Scopus, Web of Science, Embase, and SciElo from January 2019 to June 2025, applying inclusion and exclusion criteria to achieve the stated objectives. Forty relevant references were included, following the EQUATOR guidelines.
Results: This paper describes current staging and resectability criteria, the role of multidisciplinary committees, patient selection for surgical resection, the use of neoadjuvant therapy, the impact of modern surgical techniques, adjuvant therapies, postoperative follow-up, and the emerging role of personalized medicine.
Conclusions: A multidisciplinary approach represents the essential pillar for optimizing the treatment of resectable and locally advanced pancreatic cancer. Coordinated integration of specialties allows for more precise selection of patients eligible for surgery, reduces complications, and improves survival. Constantly updating diagnostic and therapeutic strategies is key to addressing the clinical challenges of this disease.

Downloads

Download data is not yet available.

References

1. Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A, Bray F, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. American Cancer Society Journals [Internet]. 2021;71(3):209-49. [access: 01/05/2025]. Available from: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21660

2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. American Cancer Society Journals [Internet]. 2022 72(1):7-33. [access: 16/06/2025]. Available from: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21708

3. Puckett Y, Garfield K. Pancreatic cancer [Internet]. United States of America: National Library of Medicine; 2024. [access: 16/06/2025]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK518996/

4. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. The Lancet [Internet]. 2020;395(10242):2008-20. [access: 16/06/2025]. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30974-0/fulltext

5. Schepis T, De Lucia SS, Pellegrino A, Gaudio A, Maresca R, Coppola G, et al. State-of-the-Art and Upcoming Innovations in Pancreatic Cancer Care: A Step Forward to Precision Medicine. Cancers [Internet]. 2023;15(13):3423. [access: 16/06/2025]Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10341055/

6. Sohal DP, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, et al. Metastatic pancreatic cancer: ASCO guideline update. Journal of Clinical Oncology [Internet]. 2020;38(27):3217-31. [access: 16/06/2025]. Available from: https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.01364

7. Versteijne E, Suker M, Groothuis K, Janine MA, Marc GB, Bert AB, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. Journal of Clinical Oncology [Internet];38(16):1-12. 2020 [access: 20/06/2025]. Available from: https://ascopubs.org/doi/pdf/10.1200/JCO.19.02274

8. Cecchini M, Salem RR, Robert M. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer A Nonrandomized Clinical Trial. JAMA Oncology [Internet]. 2024;10(8):1027-35. [access: 20/06/2025]. Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2820217

9. Drake J, Anaya, DA, Fleming JB, Denbo JW. Surgery for Borderline Resectable Pancreatic Ductal Adenocarcinoma Preoperative Planning, Technical Considerations, and Building a Program. Surgical Clinics [Internet]. 2024 [access: 20/06/2025];104(5)1031-48. Available from: https://www.surgical.theclinics.com/article/S0039-6109(24)00100-2/abstract

10. Cortina V, Vallabhaneni H, Gambill J, Nadar S, Itodo K, Park Ch, et al. Advancing Pancreatic Cancer Surgical Treatments and Proposal of New Approaches. Cancers [Internet]. 2024;16(16):2848-60. [access: 20/06/2025]. Available from: https://www.mdpi.com/2072-6694/16/16/2848

11. Takahashi S. Perioperative treatments for borderline resectable pancreatic cancer. Annals of Oncology [Internet]. 2021;32(4):265. [access: 20/06/2025]. Available from: https://www.annalsofoncology.org/article/S0923-7534(21)01669-0/fulltext

12. Abreu LF, Gryspeerdt F, Rashidian N, Hove K. Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities? BMC Surgery [Internet]. 2023;23(1):296-308. [access: 04/07/2025]. Available from: https://www.researchgate.net/publication/374328833_Predictive_factors_for_survival_in_borderline_resectable_and_locally_advanced_pancreatic_cancer_are_these_really_two_different_entities

13. Rangelova E, Stoop TF, Ramshorst TM. Del Chiaro, M. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Annals of Oncology [Internet]. 2025;36(5):529-42. [access: 04/07/2025]. Available from: https://www.annalsofoncology.org/article/S0923-7534(25)00004-3/fulltext

14. Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe Ch. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. The Lancet [Internet] 2023;8(2):157-68. [access: 04/07/2025]. Available from: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(22)00348-X/fulltext

15. Conroy T, Castan F, Lopez A, Turpin A, Abdelghani M, Wei AC, et al. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer A Randomized Clinical Trial. JAMA Oncology [Internet]. 2022;8(11):1571-8. [access: 04/07/2025]. Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2795978

16. Tanially E, Cendera C, Cheryl A, Tejayadi J, Wijaya D, Pramana A. Efficacy and safety of FOLFIRINOX in comparison to gemcitabine as adjuvant therapy for PC patients: a systematic review. Annals of Oncology [Internet]. 2024;35(3):1329. [access: 04/07/2025]. Available from: https://www.annalsofoncology.org/article/S0923-7534(24)01290-0/fulltext

17. Botta GP, Huynh TR, Spierling-Bagsic SR, Agelidis A, Schaffer R, Lin Ray, et al. Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients. Cancer Medicine [Internet]. 2022;12(7):7713-23. [access: 17/07/2025]. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.5523

18. Klein Brill A, Amar Farkash S, Lawrence G. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. JAMA Network [Internet]. 2022;5(6):16199. [access: 17/07/2025]. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793152

19. Chun JW, Lee SH, Kim JS, Park N, Huh N, Cho IR, et al. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach. BMC Cancer [Internet]. 2021 21(537):1-11. [access: 17/07/2025]. Available from: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08277-7

20. Zureikat AH, Beane JD, Zenati MS, Abbas AI, Boone BA, Moser AJ, et al. 500 Minimally Invasive Robotic Pancreatoduodenectomies. National Library of Medicine [Internet]. 2021];273(5):966-72. [access: 17/07/2025Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7871451/

21. Tang YCh, Liu QQ, He YG, Li J, Huang XB. Laparoscopic pancreaticoduodenectomy: a retrospective study of 200 cases and the optimization of the single-center learning curve. Translational Cancer Research [Internet]. 2021;10(7):3436-47. [access: 17/07/2025]. Available from: https://tcr.amegroups.org/article/view/53023/html

22. Tuveson D, Allen P. The evolving role for surgery in pancreatic cancer. Carcinogenesis [Internet]. 2024;45(11):823-5. [access: 17/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/39514563/

23. Vaalavuo Y, Siiki A, Antila A, Rinta-Kiikka I, Sanda J, Laukkarinen J. The European evidence-based guidelines on pancreatic cystic neoplasms (PCN) in clinical practice: The development of relative and absolute indications for surgery during prospective IPMN surveillance. Pancreatology [Internet]. 2020;20(7):1393-8. [access: 17/07/2025]. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1424390320307031

24. Neilson T, Cloyd JM. Neoadjuvant mFOLFIRINOX for resectable pancreatic cancer: increasing evidence, ongoing challenges. Translational Gastroenterology and Hepatology [Internet]. 2025;10(22):1027. [access: 22/07/2025]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12056118/

25. Williet N, Saint A, Pointet AL, Tougeron D, Pernot S, Pozet A. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Therapeutic Advances in Gastroenterology [Internet]. 2019;12(19):1-9. [access: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/31598136/

26. Okano N, Sakamaki K, Mie T, Watanabe K, Kobayashi S, Todaka A. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity score-matched análisis [Internet]. Japan: Elsevier; 2025. [access: 22/07/2025]. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1424390325005915?dgcid=rss_sd_all

27. Ben Q, Sun Y, Liu J, Wang W, Zou D, Yuan Y. Nicotine promotes tumor progression and epithelial-mesenchymal transition by regulating the miR-155-5p/NDFIP1 axis in pancreatic ductal adenocarcinoma. Pancreatology [Internet]. 2020;20(4):698-708. [access: 22/07/2025]. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1424390320301332

28. Nevala Plagemann C, Hidalgo M, Garrido Laguna I. From state-of-the-art treatment to novel therapies for advanced-stage pancreatic cancer. National Library of Medicine [Internet]. 2020;17(2):108-23. [access: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/31705130/

29. Rosado JE, Sohn ASW, Biancur DE, Lin EY, Osorio V, Rodrick T, et al. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. National Library of Medicine [Internet]. 2024;5(1):85-99. [access: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/37814010/

30. Goess R, Jäger C, Perinel J, Pergolini I, Demir E, Safak O, et al. Lymph node examination and survival in resected pancreatic ductal adenocarcinoma: retrospective study. BJS Open [Internet]. 2024;8(1):234. [access: 22/07/2025]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10810280/

31. Formelli MG, Palloni A, Tavolari S, Deiana, Ch, Andrini E, Di Marco M, et al. Classic versus innovative strategies for immuno-therapy in pancreatic cancer. Advanced Drug Delivery Reviews [Internet]. 2025;225(25):1-20. [access: 22/07/2025]. Available from: https://www.sciencedirect.com/science/article/pii/S0169409X25001565

32. Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: Challenges and opportunities. Gastroenterology [Internet]. 2019;156(7):2056-72. [access: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/30660727/

33. Prattico F, Garajová I. Focus on Pancreatic Cancer Microenvironment. Curr Oncol [Internet]. 2024;31(8):4241-60. [access: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/39195299/

34. Bear AS, Vonderheide RH, O'Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell [Internet]. 2020;38(6):788-802. [acceso: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/32946773/

35. Li Y, Tang J, Jiang J, Chen Z. Metabolic checkpoints and novel approaches for immunotherapy against cancer. Int J Cancer [Internet]. 2021;150(2):195-207. [access: 22/07/2025]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9298207/

36. Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: An update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol [Internet]. 2020;17(8):487-505. [access: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/32393771/

37. Sherpally D, Manne A. Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies. Cancer Immunotherapy in Clinical and Translational Research [Internet]. 2025;17(4):589. [access: 22/07/2025]. Available from: https://www.mdpi.com/2072-6694/17/4/589

38. Delitto D, Wallet SM, Hughes SJ. Targeting the pancreatic cancer immune microenvironment. Surg Oncol Clin N Am [Internet]. 2019;19(6):473-82. [acceso: 22/07/2025]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6548630/

39. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov [Internet]. 2019;18(3):197-218. [access: 22/07/2025]. Available from: https://pubmed.ncbi.nlm.nih.gov/30610226/

40. Di Marco M, Frassineti GL, Clavien PA. Critical analysis of current guidelines for the management of pancreatic cancer. Pancreatology [Internet]. 2021;21(8):1571-82. [access: 22/07/2025]. Available from: https://www.pancreatologyjournal.org/article/S1424-3903(21)00229-7/fulltext

Downloads

Published

2025-10-15

How to Cite

1.
Blanco Sosa RL, El Achtar O, Sánchez García MM, Garcia Martin CD. Current Strategies for the Multidisciplinary Management of Resectable and Locally Advanced Pancreatic Cancer. Arch Hosp Univ "Gen Calixto García” [Internet]. 2025 Oct. 15 [cited 2025 Oct. 20];13(3). Available from: https://revcalixto.sld.cu/index.php/ahcg/article/view/1606

Issue

Vol. 13 No. 3 (2025): Septiembre - diciembre (...en progreso)

Section

Artículos de Revisión

License

Copyright (c) 2025 Roberto Lázaro Blanco Sosa, Olivia El Achtar, Milton Manuel Sánchez García , Carlos David Garcia Martin

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:

  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia Creative Commons Atribución– No Comercial 4.0 que permite el uso, distribución y reproducción no comerciales y sin restricciones en cualquier medio, siempre que sea debidamente citada la fuente primaria de publicación.
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada.